Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Targeted Therapy Development (Nuclear Export Inhibition).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for XPO1 (Exportin-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XPO1 (CRM1) Full-Length Recombinant Protein (WT, C528S, E571K mutants). High purity (>95%), Endotoxin <1EU/µg. Expressed in HEK293 or Baculovirus/Insect Cell systems for native conformation and binding studies. | View XPO1 Products |
| Gene Delivery | XPO1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation. CMV promoter, Puromycin selection marker included. | View XPO1 Products |
| Benchmark Ab | Anti-XPO1 Monoclonal Antibody (Research Grade). Recombinant rabbit monoclonal for Western/IP/ICC validation. | View XPO1 Products |
| Validator | XPO1 siRNA Set (3 unique sequences). For knockdown and specificity verification in cellular assays. | View XPO1 Products |
| Related Target: p53 | Key tumor suppressor exported by XPO1. Functional nuclear export assay cargo. | View p53 Products |
| Related Target: FOXO3 | Nuclear transcription factor regulated by CRM1-mediated export; cell apoptosis pathway marker. | View FOXO3 Products |
| Related Target: XPO4 | Exportin 4 Recombinant Protein for selectivity/counter-screening against XPO1 paralogs. | View XPO4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Drug Resistance (C528S / E571K Hotspots) | Site-specific mutant proteins (C528S, E571K) expressed in HEK293 or Baculovirus with >95% purity for binding screens and selectivity testing. Sequence verified, theoretical MW confirmed by Mass Spec. |
| Intracellular Target Conformation | Baculovirus/Insect Cell Expressed to preserve complex folding and native state. Also available in HEK293 expression. |
| Selectivity vs. Other Exportins | Homolog panel available: XPO4, XPO5, etc. for counter-screening to ensure specificity. |
| Validated Reagents & Controls | Recombinant positive control antibodies and validated siRNA included for specificity checks and assay validation. |
Live XPO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XPO1 therapeutics is intensifying, with major players shifting focus from early-generation SINEs (Selective Inhibitors of Nuclear Export) to next-generation small molecules with improved tolerability. As first-generation therapies reach the clinic, the next wave of R&D is targeting mutant-specific resistance and combination therapies with targeted biologics. First-generation SINEs like Selinexor have exhibited dose-limiting toxicities (e.g., thrombocytopenia, gastrointestinal effects), prompting development of second-generation inhibitors (e.g., Eltanexor) with better therapeutic windows. Resistance mutations such as C528S and E571K are being actively addressed through novel inhibitor designs, including non-covalent binders and PROTAC degraders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SINE) | Karyopharm, Antengene | Multiple Myeloma, DLBCL | Selectivity Assay (Need Mutant vs WT Proteins) |
| Next-Gen Inhibitors | Karyopharm | Solid Tumors | Binding Affinity (Need high-purity recombinant proteins) |
| PROTAC / Degrader | Emerging Biotechs | Refractory Cancers | Degradation Assays (Need Stable Cell Lines) |